SLEURO TODAY

Home / Science & Publications

Blocking interferon works on many types of skin lupus even when all other therapies have failed

Comment on: Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Changes in Discrete Subsets of Blood Transcriptomic and Cellular Biomarkers Comment by: Professor Edward Vital, Associate Professor in Systemic Lupus Erythematosus at University of Leeds. Chair of BILAG and the Lupus Forum.   Anifrolumab has been shown to be effective … Read more

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study

Comment on: “Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.” Tian J, et al. Ann Rheum Dis 2023;82:351–356. doi:10.1136/ard-2022-223035. “Systemic lupus erythematosus incidence and prevalence in a large population-based study in northeastern Italy.” Zen M, et al. Rheumatology 2022 (published online: Dec 10). doi: 10.1093/rheumatology/keac685. Commented by: Luís S. Inês, … Read more

Always listen to our haematology colleagues!

Comment on: “Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus”. Mackensen A et al.  Nature Medicine 2002; 28: 2124. Commented by: Frédéric A. Houssiau. Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Bruxelles. Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, UCLouvain. This article by the group of Georg Schett in Erlangen … Read more

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports

Comment on: “Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports“. Petri M, et al. Ann Rheum Dis 2022;0:1–9. doi:10.1136/annrheumdis-2022-222505 Commented by: Angela Tincani, Rheumatology and Clinical Immunology, ASST-Spedali Civili and University of Brescia, Italy Pregnancy is a hot problem in women … Read more

Stopping versus continuing maintenance immunosuppressive therapy in lupus nephritis at 2-3 years

Comment on: “Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial” (Ann Rheum Dis. 2022 Jun 20; doi: 10.1136/annrheumdis-2022-222435) Commented by: Maria G. Tektonidou, Professor of Rheumatology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece Lupus nephritis (LN) is … Read more

Lack of efficacy of ustekinumab in a phase 3 randomised controlled trial in patients with systemic lupus erythematosus

Comment on: “Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus” (Ann Rheum Dis. 2022; doi: 10.1136/ard-2022-222858) Commented by: Maria G. Tektonidou, Professor of Rheumatology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece Patients with systemic … Read more

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Comment on: Werth et al., N Engl J Med 2022;387:321-31. DOI: 10.1056/NEJMoa2118024 Commented by: Elisabet Svenungsson In clinical practice it is often a challenge to treat cutaneous lupus erythematosus (CLE), especially the discoid and chronic lesions are commonly very resistant to treatment. These lesions cause irreversible damage, which has great impact on the quality of … Read more

Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role of genetic factors in the lupus-associated DNA methylation signature

Comment on: Coit, et al., Ann Rheum Dis 16 June 2022. doi:10.1136/annrheumdis-2022-222656 Comment by: Marta E. Alarcón-Riquelme Epigenetics, and particular the study of the methylation of the CpG nucleotides in DNA has shown that lupus CD4+ T cells have aberrant methylation patterns1 and are poised towards activation of interferon-regulated genes2. DNA methylation is an important … Read more

Combined genetic deficiencies of the classical complement pathway are strongly associated with both systemic lupus erythematosus and primary Sjögren´s syndrome

Comment on: Lundtoft, et al., Arthritis Rheumatol, June 21 2022 (Accepted) DOI: 10.1002/art.42270 Comment by: Marta E. Alarcón-Riquelme Since long ago, we are aware that complement deficiencies are related with the appearance of SLE, particularly in the youth. However, we are not completely aware of the role of complement deficiencies in relation to the risk … Read more